文献速递泌尿生殖与妇科肿瘤放疗

高危前列腺腺癌新辅助雄激素剥夺治疗后的前列腺特异性抗原反应(PIRANHA):两项随机临床试验的汇总分析

Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-12-25

该研究汇总分析了两项多中心随机临床试验(TROG 03.04 RADAR 和 PCS IV)中 930 例接受根治性放疗的高危前列腺癌患者,评估新辅助雄激素剥夺治疗(ADT)至少 3 个月后 PSA 反应不佳(PSA >0.5 ng/mL)对长期结局的预后影响。中位随访 130 个月,57% 的患者 PSA >0.5 ng/mL,PSA 反应不佳与更差的转移无生存、生化复发、前列腺癌特异性死亡和总生存显著相关。作者结论认为 PSA >0.5 ng/mL 的患者应考虑治疗强化。

要点

  • 高危前列腺癌患者新辅助 ADT 至少 3 个月后 PSA >0.5 ng/mL 占 57%。
  • PSA 反应不佳与更差的转移无生存(HR 3.93)、生化复发(sHR 2.39)、前列腺癌特异性死亡(sHR 1.50)和总生存(HR 4.51)相关。
  • 作者认为 PSA >0.5 ng/mL 的患者应考虑治疗强化。

核心结论

  • 高危前列腺癌患者接受至少 3 个月新辅助 ADT 后 PSA >0.5 ng/mL 与更差的长期临床结局相关,作者认为应考虑治疗强化。

研究设计与样本

  • 本分析为多中心随机临床试验 TROG 03.04 RADAR 和 PCS IV 的事后分析,纳入 930 例高危前列腺癌患者。
  • 纳入标准为高危前列腺癌(Gleason 评分 ≥8、初始 PSA ≥20 ng/mL 或 cT3a 及以上)、接受根治性放疗、至少 18 个月 ADT,并在至少 3 个月新辅助 ADT 后、放疗前检测 PSA。

主要发现

  • 中位随访 130 个月(四分位距 89-154 个月),新辅助 ADT 中位 3 个月(四分位距 3-4.2 个月)后,中位 PSA 为 0.60 ng/mL(四分位距 0.29-1.59)。
  • 535 例(57%)患者 PSA >0.5 ng/mL。
  • PSA 反应不佳与更差的转移无生存相关(HR 3.93;P = .02)。
  • PSA 反应不佳与更差的生化复发相关(亚分布 HR 2.39;P = .003)。
  • PSA 反应不佳与更差的前列腺癌特异性死亡相关(亚分布 HR 1.50;P = .005),与更差的总生存相关(HR 4.51;P = .05)。

关键数值与推荐

  • PSA 反应不佳定义为新辅助 ADT 至少 3 个月后 PSA >0.5 ng/mL。
  • 高危前列腺癌定义为 Gleason 评分 ≥8、初始 PSA ≥20 ng/mL 或 cT3a 疾病或更高。

临床怎么用

  • 作者认为,至少 3 个月新辅助 ADT 后 PSA >0.5 ng/mL 的患者长期临床结局更差,应考虑治疗强化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A suboptimal prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) among men who go on to receive definitive radiation therapy for prostate cancer might suggest the existence of castration-resistant disease or altered androgen receptor signaling. This in turn may portend worse long-term clinical outcomes, especially in men with high-risk disease. We set out to evaluate the prognostic impact of poor PSA response to neoadjuvant ADT in men with high-risk prostate cancer. METHODS AND MATERIALS: This was a post hoc analysis of the multicenter TROG 03.04 RADAR and PCS IV randomized clinical trials. Inclusion criteria for this analysis were patients with high-risk prostate cancer (defined as Gleason score ≥8, initial PSA ≥20 ng/mL, or cT3a disease or higher) who received definitive radiation therapy, at least 18 months of ADT, and had a preradiation therapy PSA level drawn after at least 3 months of neoadjuvant ADT. Poor PSA response was defined as PSA >0.5 ng/mL. Cox regression and Fine-Gray models were used to test whether poor PSA response was associated with metastasis-free survival, biochemical recurrence, prostate-cancer specific mortality, and overall survival. RESULTS: Nine hundred thirty men met inclusion criteria for this analysis. Median follow-up was 130 months (interquartile range [IQR], 89-154 months). After a median of 3 months (IQR, 3-4.2 months) of neoadjuvant ADT, the median PSA was 0.60 ng/mL (IQR, 0.29-1.59). Overall, 535 men (57%) had a PSA >0.5 ng/mL. Poor PSA response was associated with significantly worse metastasis-free survival (hazard ratio [HR], 3.93; P = .02), worse biochemical recurrence (subdistribution HR, 2.39; P = .003), worse prostate-cancer specific mortality (subdistribution HR, 1.50; P = .005), and worse overall survival (HR, 4.51; P = .05). CONCLUSIONS: Patients with PSA >0.5 mg/mL after at least 3 months of neoadjuvant ADT had worse long-term clinical outcomes and should be considered for treatment intensification.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nikitas J, Ong WL, Carrier N, et al. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2023. PMID: 38151191. doi:10.1016/j.ijrobp.2023.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。